Quantcast
Last updated on April 24, 2014 at 13:57 EDT

Latest adjuvant therapy Stories

2013-06-03 08:27:25

Previstage(TM )GCC colorectal cancer test featured at the 2013 ASCO Annual Meeting QUEBEC CITY, June 3, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) today reported that results of a new study were presented on Sunday, June 2, during the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois. The abstract of the presentation entitled "Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage...

2013-05-31 12:24:08

IRVINE, Calif., May 31, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago. Of particular importance are the studies which demonstrate that molecular subtyping allows for improvement in therapy selection and overall...

2013-05-31 08:24:39

Prognostic Information from Oncotype DX in Metastatic Breast Cancer Indicates Importance of Biology Revealed by the Test Across Continuum of the Disease REDWOOD CITY, Calif., May 31, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of 10 studies being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring the company's commitment to optimizing cancer treatment. New data include studies of the Oncotype DX®...

2013-05-16 08:27:22

New findings validate clinical utility in Colorectal Cancer Staging MONTREAL, May 16, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"), today announced that results from a large validation study of the Previstage(TM) GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology((R)) (ASCO((R))) Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013. The results of the...

2013-05-07 00:20:31

Guideline provides detailed direction on treatment options for prostate cancer patients SAN DIEGO, May 7, 2013 /PRNewswire/ -- The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence. The 81-page document represents an intensive collaboration among experts in the radiation...

2013-04-17 08:26:36

Findings of CALGB 9581 Published in the Journal of Clinical Oncology Support Expansion of Colon Cancer Reimbursement and Broader Patient Access REDWOOD CITY, Calif., April 17, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology (JCO) published positive results from the large CALGB 9581 clinical validation study of the Oncotype DX® colon cancer test in stage II colon cancer patients. The findings provide further...

2013-03-18 11:15:32

At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers in the development of chemo resistance in bladder cancer. Neoadjuvant cisplatin-based chemotherapy is recommended for patients with muscle invasive bladder cancer. Cisplatin-based regimes have similar efficacy with complete response in 30% a survival advantage if 16%...

2013-03-15 08:26:42

New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients REDWOOD CITY, Calif. and ST. GALLEN, Switzerland, March 15, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of results from 22 studies at the 13(th) St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX® breast cancer test around...

2013-03-13 08:33:48

Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy REDWOOD CITY, Calif., March 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive...

2013-01-23 08:28:57

REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of the Oncotype DX(®) Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score(®) (RS) results changed treatment recommendations in 45 percent of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis suggesting...